TransCode Therapeutics, Inc. (RNAZ)
NASDAQ · Manufacturing · Pharmaceutical preparations
$1.67+$0.0200 (+1.21%) on the dayAs of the close; data may be delayed.
RNAZ price, last 12 months
Key stats
- Previous close
- $1.65
- Open
- $1.65
- Day range
- $1.60 – $1.70
- 52-week range
- $1.58 – $20.99
- Volume
- 9K
- Avg volume (20 days)
- 96K
- Market cap
- $28.6M
Performance
1W+1.2%
1M−28.6%
3M−63.3%
6M−80.4%
YTD−75.6%
1Y−85.7%
vs S&P 500, 1Y−102.5 pts
Technicals and fundamentals
About TransCode Therapeutics, Inc.
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $28.6M